No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 1.9500
- -0.4300-18.07%
Close Dec 20 16:00 ET
- 1.9000
- -0.0500-2.56%
Post 20:01 ET
4.62MMarket Cap-0.29P/E (TTM)
2.2851High1.7800Low262.54KVolume2.2300Open2.3800Pre Close531.69KTurnover17.51%Turnover RatioLossP/E (Static)2.37MShares24.336052wk High-0.50P/B2.92MFloat Cap1.730052wk Low--Dividend TTM1.50MShs Float294.0000Historical High--Div YieldTTM21.22%Amplitude1.7300Historical Low2.0250Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
NLS Pharmaceutics and Kadimastem Advance Diabetes Treatment With FDA Submission
NLS Pharmaceutics And Kadimastem In Collaboration With ITolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For ITOL102 For Type 1 Diabetes
NLS Pharmaceutics Plans Capital Increase at Extraordinary Shareholders' Meeting
NLS Pharmaceutics Expects to Close Kadimastem Merger by End of January
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans
Which Subsectors to Own and Which to Avoid – Wolfe Research
Heat List
US
Overall
Symbol
Price
% Chg
No Data